Jonathan Aschoff
Stock Analyst at Roth MKM
(0.66)
# 3,698
Out of 4,829 analysts
43
Total ratings
25.71%
Success rate
-31.95%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.30 | +378.26% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $7.76 | +170.62% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $0.34 | +86,958.82% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.84 | +878.26% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $1.00 | +1,600.00% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.69 | +2,562.72% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.93 | +2,055.17% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $3.55 | +209.86% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $1.03 | +3,783.50% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.26 | +10,607.46% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $6.45 | +458.14% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $360 | $4.20 | +8,471.43% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.74 | +422.65% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $2.68 | +7,362.69% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.08 | +573.08% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $3.32 | +216,774.00% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.70 | +1,048.27% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.00 | +4,899.75% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.69 | +58,294.16% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $5.42 | +601.11% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24,000 | $0.83 | +2,891,466.27% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.92 | +4,900.00% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.59 | +71.28% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.30
Upside: +378.26%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $7.76
Upside: +170.62%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $0.34
Upside: +86,958.82%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.84
Upside: +878.26%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $1.00
Upside: +1,600.00%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.69
Upside: +2,562.72%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.93
Upside: +2,055.17%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $3.55
Upside: +209.86%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $1.03
Upside: +3,783.50%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.26
Upside: +10,607.46%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $6.45
Upside: +458.14%
Mar 5, 2024
Maintains: Buy
Price Target: $75 → $360
Current: $4.20
Upside: +8,471.43%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.74
Upside: +422.65%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $2.68
Upside: +7,362.69%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.08
Upside: +573.08%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $3.32
Upside: +216,774.00%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.70
Upside: +1,048.27%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.00
Upside: +4,899.75%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.69
Upside: +58,294.16%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $5.42
Upside: +601.11%
Feb 12, 2021
Initiates: Buy
Price Target: $24,000
Current: $0.83
Upside: +2,891,466.27%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.92
Upside: +4,900.00%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $7.59
Upside: +71.28%